Skip to main content
Premium Trial:

Request an Annual Quote

Axela, Beckman Coulter, Sigma-Aldrich, Tm Bioscience, Applied Imaging, Genetix, Eurofins-Medigenomix-MWG Biotech

Axela Licenses Beckman Technology for Biomarker Validation
 
Biomarker validation company Axela Biosensors has nonexclusively licensed Beckman Coulter’s Universal Linker Capture technology, the companies said this week.
 
Axela plans to use the technology in conjunction with its dotLab sensors to allow users to define their own biomarker panels and to use either the Axela library of pre-conjugated antibodies or their own reagents with universal linkers.
 
Axela CEO Rocky Ganske added that using the technologies will “allow users to tag their own antibodies or draw from a library of existing markers to build combined assays with micromolar to picomolar sensitivity requirements."
 
Financial terms of the deal were not released.
 

 
Sigma-Aldrich Unit to Distribute MIP’s Separation Products
 
Sigma-Aldrich said this week that its Supelco division will exclusively distribute MIP Technologies’ separation products worldwide.
 
Specifically, the deal includes MIP’s Molecularly Imprinted Polymer separation products. The companies also will collaborate on developing new products.
 
Financial terms of the alliance were not disclosed.
 

 
Tm Bioscience Secures $4M Credit Facility
 
Tm Bioscience said last week that it has negotiated a $4 million operating credit facility with Laurus Master Fund.
 
Tm said it plans to use the funds for general operating purposes while its board of directors completes its previously disclosed review of the company’s strategic alternatives, which include the sale or merger of the company.
 
As of Sept. 30, Tm had around $4.7 million in cash and cash equivalents.
 
Net funds available to the company through the credit facility after transaction costs are around $3.85 million.
 
The facility, which matures on Aug. 31, 2007, is secured by a charge over Tm's assets and carries an interest rate of 7 percent. 
 
The interest rate will decrease in relation to increases in the company's share price over the term of the facility to a minimum interest rate of 0 percent.
 

 
Applied Imaging Shareholders OK Acquisition by Genetix
 
Applied Imaging shareholders have approved the sale of the company to Genetix Group, AI said last week.
 
The all-cash deal is valued at $25.8 million. Genetix will pay $4.20 for each share of Applied Imaging's common stock.
 
Since announcing the deal in September, Genetix has raised its original bid price of $3.03 several times in response to unsolicited bids by at least one third-party to purchase Applied Imaging.
 
The companies did not say when they expect the deal to close.
 

 
Eurofins-Medigenomix-MWG Biotech Buys 454 Instrument
 
Eurofins-Medigenomix-MWG Biotech has acquired a 454 Life Sciences Genome Sequencer 20 instrument from Roche and expects to install it next week in Medigenomix’s German research facility, the companies said last week. 
 
By combining the GS20 with the companies’ current sequencing platform, which is “mainly based” on the Sanger method, MWG and Medigenomix will be able to sequence and compare bacterial genomes in “a couple of days.”
 
MWG Biotech, based in Ebersberg, Germany, performs DNA sequencing services, and in August 2005 it joined forces with Eurofins Medigenomix, which outsourced DNA-analysis services for biopharma companies and academic institutions.
 
The deal makes Eurofins-Medigenomix-MWG Biotech the first sequencing provider in Germany using GS20 in-house. The placement comes a few weeks after another German company, Konstanz-based GATC Biotech, said it reached a licensing agreement to use the GS20 for sequencing and for mutation analysis. It was not immediately clear if GATC has placed a GS20 in-house.
 
Financial terms of the Eurofins-Medigenomix-MWG Biotech deal were not released.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.